Dongwha Pharm-MSD Korea signs license agreement of antidepressant ‘Remeron’
Dongwha Pharm(CEO Ji-Hoon Sohn) signed a MSD’s exclusive sale and supply agreement of Remeron(generic name: mirtazapine), a MSD’s antidepressant, in Korea on the 8th of September.
Remeron, a MSD’s NaSSA(antidepressant with the Noradrenergic and Specific Serotonergic Antidepressants) mechanism, w...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.